Zhejiang Jingxin Pharmaceutical's strong financials, higher than average ROE, decent net income growth, and efficient reinvestment of earnings could potentially boost its stock value. Analysts expect earnings to gain momentum.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more